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The p53 tumor suppressor protein, one of the most extensively studied proteins, plays a pivotal role
in cellular checkpoints that respond to DNA damage to prevent tumorigenesis. However, the tran-
scriptional control of the p53 gene has not been fully characterized. We report that the transcription
factor E2F1 binds only to the E2F1 distal site of the p53 promoter in the human papillomavirus posi-
tive carcinoma HeLa cell line. Moreover, we showed that etoposide, a DNA damaging agent, activates
p53 transcription through the E2F1 pathway. This increase correlates with apoptosis induction as
disruption of this pathway led to reduced apoptosis stimulation by the DNA damaging agent.
 2013 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction
The tumor suppressor p53 plays a crucial role to maintain gen-
ome integrity as it can: (i) induce cell growth arrest by holding cells
at the G1/S checkpoint, (ii) activate DNA repair on damaged DNA,
(iii) induce apoptosis if DNA damage is irreparable [1]. The exposure
of a cell to a genotoxic stress leads to an increase of activated p53
protein levels [2]. Activated p53 works as a transcription factor that
can bind DNA and induce the transcription of hundreds of down-
stream genes including cell cycle and apoptosis regulators [3].
It is well described that the increase and regulation of p53 level
in DNA damaged cells occurs at the protein level. This includes
translational control, post-translational modiﬁcations, protein–
protein interactions and sub-cellular localization [4–6]. These
mechanisms allow a rapid cellular response to the stress. Surpris-
ingly, the transcriptional regulation of the p53 gene under geno-
toxic stress is poorly documented even if it has been
demonstrated for a long time [7]. Only few studies have reported
the identiﬁcation of transcriptional factors involved in p53 regula-
tion. Thus, p53 itself or p73 can bind the p53 promoter region
(Fig. 1A) producing a positive feedback loop activated under stress
conditions [8]. Another transcriptional factor involved in p53 cellu-
lar stress response is E2F1. Two E2F1 binding sites namely E2F1-
BS-1 and E2F1-BS-2, have been reported within the p53 promoter(Fig. 1A). The proximal binding site (E2F1-BS-1) has been described
by Choi et al. [9] and recently the second distal binding site (E2F1-
BS-2) has been discovered by Bug and Dobbelstein [10]. In the lat-
est work, the authors showed that E2F1 contributes to p53 tran-
scriptional activation under anthracycline treatment through the
binding at the proximal site in a Human Papillomavirus (HPV) neg-
ative cell line expressing a mutated p53 protein. However in this
cell line, etoposide, another topoisomerase inhibitor failed to acti-
vate p53 transcription.
In this work, in a HPV positive model and in a wild type p53
background, we report that E2F1 distal site (E2F1-BS-2) accounted
for p53 transcription. Moreover, its transcription was activated by
etoposide treatment through E2F1 binding at the distal site (E2F1
BS-2). In this model, p73 another E2F1 target, slightly contributed
to the increase of p53 mRNA level. Finally, we showed that acti-
vated E2F1 pathway upon etoposide treatment participate to the
induction of apoptosis through the activation of p53 transcription.
2. Materials and methods
2.1. Cell line, drug treatments and transfections
HeLa (ATCC: CCL-2) cell line was grown in DMEM 1 g/l glucose
supplemented with 10% fetal bovine serum, 1% glutamine and anti-
biotics, at 37 C in a 5% CO2 humidiﬁed atmosphere. When indi-
cated, cells were incubated for 16 h in growth medium with 25
or 50 lM of etoposide (Biotrend).
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Fig. 1. E2F1 induces p53 transcription trough its distal binding site. (A) Partial representation of the p53 promoter sequence. The transcriptional start site (+1) is represented
by the arrow. Two potential E2F1 binding sites are represented: E2F1 BS-1 (proximal), E2F1 BS-2 (distal) and a p53/p73 binding site. (B–D) ChIP experiments were performed
using antibodies directed against E2F1, or IgG (NRS) as a negative control and quantitative PCR were performed using primers that amplify the potential indicated binding
sites. (B) E2F1 binding on the p53 promoter. (C) E2F1 binding on the SKP2 promoter (P) as a positive control (right) and in a region 1.5 kb upstream of the SKP2 transcriptional
start site (negative control). (D) E2F1 binding on the cyclin E promoter (P, positive control). (E) Schematic representation of the luciferase fusions including 50 deletion
mutants of the p53 promoter harboring the indicated binding sites for E2F1 and p53/p73. The cross indicates a disrupted BS-2 site. (F) Responsiveness of the luciferase fusions
represented in (E) towards E2F1 overexpression. (G) Western blot experiments to assess E2F1 and p53 expression in Hela cells when pTTE2F1 is co-transfected with the
indicated constructs. (H) RT-qPCR analysis of p53 and p73 mRNA levels. Experiments were done in triplicates (⁄P < 0.05).
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agents (Polyplus transfection) according to the manufacturer’s
instructions. siRNAs targeting sequences were as follow: E2F1 50-
GUCACGCUAUGAGACCUCAdTdT-30; p53 50-GGAAACUACUUCCU-
GAAAAdTdT-30; p73 50-GGGACUUCAAUGAAGGACAdTdT-30; SCR
50-CUACAAGAUUUGUGACGUAdTdT30.2.2. Luciferase reporter assay
Cells were co-transfected with the indicated p53 promoter con-
structs pGL3-100 bp; pGL3-200 bp; pGL3-1.2; pGL3-1.2 mutBS-2
(BS-2 was mutagenized with Quick Change XL using BS2 mut F
and BS2 mut R as primers (primer sequences: Table 1) and pGL3-
3190 A. Massip et al. / FEBS Letters 587 (2013) 3188–31941.2 as template; Ref. 200522; Agilent technologies); pGL2-CyclinE
(300 ng) or empty plasmid (pGL3) and 300 ng of E2F1 expression
vector (pTT-E2F1) or empty vector. 24 h after transfection, cells
were lyzed in Passive Lysis Buffer and ﬁreﬂy luciferase activity
was measured in a LB960 luminometer (Berthold). Light units were
normalized to the amounts of transfected plasmids quantiﬁed by
qPCR.
2.3. Western blot
Western blots were performed 48 h after transfection. Thirty
micrograms of total extracts were resolved in 4–20% polyacryl-
amide gels and transferred onto a nitrocellulose membrane. Immu-
noblotting were performed using antip53 (DO-1):sc-126 antibody,
E2F1 (C-20): sc-193 antibody (Santa Cruz), and monoclonal anti-b-
actin antibody (Sigma). The signal was detected using enhanced
chemiluminescence detection reagent.
2.4. RNA extraction and quantiﬁcation using real-time PCR
Total RNA was extracted using the TriZol reagent protocol
(Invitrogen). Reverse transcription was performed with 1 lg of to-
tal RNA using RevertAid H Minus First Strand cDNA Synthesis Kit
(Fermentas) and oligo(dT) primer. Real-time PCR was performed
with SsoFast EvaGreen Supermix with HPRT1 and GUSB mRNAs
as endogenous references (for oligonucleotide sequences see Ta-
ble 1). Assays were performed on 7500 Fast Real-Time PCR System
(Applied Biosystems). Experiments were done in triplicate and cal-
culations performed using the DDCq method.
2.5. Chromatin immuno-precipitation assay
Formaldehyde was added to the culture medium to a ﬁnal con-
centration of 1% for 10 min and glycin was added to a ﬁnal concen-
tration of 0.125 M. Cells were washed twice with cold PBS and
harvested by scraping. Cells were lysed (Pipes 5 mM pH 8, KCl
85 mM, NP-40 0.5%) and homogenized with a Dounce. Nuclei were
harvested by centrifugation, incubated in a nuclear lysis buffer
(50 mM Tris pH 8.1, 10 mM EDTA, 1% SDS), and sonicated (ﬁveTable 1
Oligonucleotide sequences.
1200Fp53 1.2kpb
188F (p53 200)
99F (p53 100)
+12R (p53)
E2F1 BS-1 F
E2F1 BS-1 R
E2F1 BS-2 F
E2F1 BS-2 R
Cyclin E F
Cyclin E R
SKP2 F
SKP2 R
SKP2-1500 F
SKP2-1500 R
pGL2/3 F
pGL2/3 R
RTqPCR HPRT1 F
RTqPCR HPRT1 R
RTqPCR GUSB F
RTqPCR GUSB R
RTqPCR p73 F
RTqPCR p73 R
RTqPCR p53 F
RTqPCR p53 R
BS2 mut F
BS2 mut Rtimes for 10 s at a power setting of 5% and 50% duty cycle; Branson
Soniﬁer 250) to obtain DNA fragments of 500–1000 bp. Samples
were diluted 10 times in dilution buffer (0.01% SDS, 1.1% Triton
X-100, 1.2 mM EDTA, 16.7 mM Tris pH 8.1, 167 mM NaCl) and
pre-cleared with 140 ll of previously blocked EZview beads (Sig-
ma). Blocking was achieved by incubating the agarose beads with
500 lg of BSA and 200 lg of herring sperm DNA for 3 h at 4 C.
Pre-cleared samples were incubated overnight at 4 C with speciﬁc
antibodies (1–2 lg) or with normal rabbit serum as negative con-
trol. Immune complexes were then recovered by incubating the
samples with 140 ll of blocked EZview beads for 2 h at 4 C on a
rotating wheel. Beads were washed once in dialysis buffer (2 mM
EDTA, 50 mM Tris pH 8, 0.2% Sarkosyl) and four times in wash buf-
fer (100 mM Tris pH 8.8, 500 mM LiCl, 1% NP-40, 1% NaDoc). Elu-
tion was performed 15 min in elution buffer (1% SDS, 100 mM
NaHCO3). Crosslink was reversed by adding SDS and RNase A to
the samples overnight at 70 C. After a 1.5 h proteinase K treat-
ment, DNA was puriﬁed with phenol/chloroform/isoamylalcool
(25:24:1) and precipitated with ethanol and NaAc.
The immunoprecipitation of DNA–protein complexes was
achieved with antibodies directed against E2F1 (sc-193, Santa
Cruz) or phosphorylated polymerase II 8A7 (sc-13583, Santa Cruz)
or with normal rabbit serum (NRS) for control experiments. Abun-
dances of target sequences were analyzed by quantitative PCR (pri-
mer sequences: Table 1). Values reﬂecting chromatin enrichment
are reported as the percent of input: immunoprecipitated with
E2F1 or phosphorylated polymerase II antibodies after normaliza-
tion to input levels.
2.6. Apoptosis assay
Apoptosis was measured with the Caspase Glo 3/7 reagent
(Promega) according to the manufacturer protocol after treat-
ment or not with etoposide at the indicated concentrations for
16 h and with a CytoGLO annexin V-FITC Apotosis detection kit
(Ref. 10085 K) from IMGENEX after treatment (+) or not 12 h
with 25 lM etoposide of Hela cells transfected with indicated
siRNA. Analysis were performed on a FACS Verse (BD
Biosciences).50-GGTACCACAGCAGTCCGGAGCTAACG-30
50-GAGCTCCGGCGAG AATCCTGACTCTG-30
50-GGTACCGCGACTGTCCAGCTTTGTGC-30
50-CCTGGACGGTGGCTCTAGAC-30
50-CCAGCTGAGAGCAAACGCAAAAGC-30
50-CTCGCCGACCTGGTGCCGTA-30
50-CCCGGATCAGATTTCGCGGGC-30
50-TACCGCGGGACTCGGTAGGG-30
50-GCCGCCCGCCGTGTTTACAT-30
50-GGCGCTGGAGC GGCAAAAAG-30
50-CGGGACGGAAACTACAATTC-30
50-AAGCCTAGCAACGTTCCATC-30
50-TCCCTCCTTAATAGCTCCCCATCCCC-30
50-CTGGGAGGCACTCGTTCGCC-30
50-GAACTTCCCGCCGCCGTTGT-30
50-TCCTCCGCGCAACTTTT TCGC-30
50-GGCTCCGTTATGGCGACCCG-30
50-AAACACCCTTTCCAAATCCTCAGCA-30
50-GATGACATCACCGTCACCACCAGC-30
50-CCCAGTCCCATTCGCCACGACT-30
50-GGACGCAGCGAAACCGGGG-30
50-CTGGGCCATCTTCCCCACGC-30
50-CCAGGGAGCACTAAGCGAGCAC-30
50-GAACATCTCGAAGCGCTCACGC-30
50-CCGCCGCATCCCGGATCAGATGATATCGGCGACCCACGGAACCCGCGG-30
50-CCGCGGGTTCCGTGGGTCGCCGATATCATCTGATCCGGGATGCGGCGG-30
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Fig. 2. Etoposide induces E2F1 dependent p53 transcription through its distal binding site and leads HeLa cells to apotosis. (A) Hela cells were transfected by either a siRNA
against E2F1 (siE2F1) or a scrambled siRNA (siSCR) and treated or not with etoposide. ChIP experiments were performed using antibodies directed against E2F1, or IgG (NRS)
as a negative control and quantitative PCR using primers that amplify the potential indicated binding sites. (B) Same conditions as in A, but the ChIP experiments were
performed using antibodies directed against active phosphorylated polymerase II or IgG (NRS) as a negative control. (C) RT-qPCR analysis of E2F1 and p53 mRNA levels in
HeLa cells transfected by scrambled or E2F1 siRNA and treated or not by etoposide. Experiments were done in triplicates (⁄P < 0.05). (D) Western blot experiments
corresponding to the same experimental conditions as described in C.
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It has been recently reported that the transcription factor E2F1
is able to bind the p53 promoter on the proximal E2F1 binding site
(BS-1, Fig. 1A) in the human U251 glioblastoma cell line which har-
bors a mutated p53 [11]. We addressed the question if E2F1 can
contribute to induce apoptosis under a genotoxic stress in a p53
wild type context by p53 transcriptional activation. To do this,
we ﬁrst investigated E2F1 binding on the p53 promoter in HeLa
cells which possess low levels of wild type p53. The two previously
described E2F1 binding sites E2F1 BS-1 and E2F1 BS-2 were sub-
jected to chromatin immunoprecipitation (ChIP) to analyse E2F1binding on the p53 promoter (Fig. 1B). E2F1 transcription factor
was found associated with the distal binding site (E2F1-BS-2),
but no binding was detected at the proximal binding site (E2F1-
BS-1). As a positive control, E2F1 was associated with the SKP2
promoter, a known E2F1 target gene (Fig. 1C). Conversely, E2F1
was not found associated with the SKP2 genomic region located
1.5 kb upstream of the transcriptional start site (negative control).
Additionally, E2F1 binding was observed for the cyclin E promoter
another E2F1 target gene (Fig. 1D). To conclude, E2F1 is able to
bind DNA at the distal site (E2F1 BS-2) of the p53 promoter in HeLa
cells but not at the proximal site as previously observed in U251
cells [10]. Interestingly, HeLa cells are HPV18 positive cells and
AB
Fig. 3. Measure of apoptosis in HeLa cells. (A) Caspase 3 and 7 activity in HeLa cells transfected with the indicated siRNAs and treated or not by etoposide. (B) FACS analysis:
evaluation of apoptosis induction in HeLa cells transfected with the indicated siRNA and treated (+) or not by etoposide (25 lM) for 12 h. Cells were stained with APC-Annexin
V and PI followed by FACS analysis to determine the percentage of apoptotic cells. Graphs are the mean of three independent experiments. White bar represents untreated
cells; black bars represent etoposide treated cells (+).
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HPVs, a protein that interacts with E2F1 and activates E2F1-driven
transcription [12]. The impact of this interaction concerning the
choice of the E2F1 binding sites on the p53 promoter region and
the efﬁciency of these binding sites on p53 transcriptional activa-
tion will be the purpose of another investigation. This will evaluate
the contribution of both HPV18 E6 or HPV18 E7 on p53 protein le-
vel in HeLa cells.
To further analyze the control of p53 transcription by E2F1, we
searched for the presence of sequences that could regulate p53
transcription in a context where E2F1 was overexpressed. For this,
four promoter constructs were generated to place different regionsof the p53 promoter upstream of the luciferase reporter (Fig. 1E).
The shortest construct (pGL3-100 bp) contains the minimal pro-
moter [8] including the proximal E2F1 binding site; the pGL3-
200 bp contains the E2F1 BS-1 and the p53/73 binding site, the
pGL3-1.2 kb contains E2F1 BS-1, BS-2 and the p53/73 binding site
and ﬁnally the pGL3-1.2 kb mutBS-2 exhibiting a mutagenized
E2F1 BS-2 site to abolish E2F1 binding. Over-expression of E2F1
in transfected HeLa cells induced a 5-fold increase of the luciferase
activity only for the 1.2 kb construct that possesses the intact
E2F1-BS2 binding site. The 200 bp construct showed a slight,
non-signiﬁcant activation of transcription compared to the wild
type 1.2 kb construct (Fig. 1F). The promoter fragment containing
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expression, thus conﬁrming that this region of the promoter is not
responsive to E2F1 in HeLa cells. As a positive control, a construct
containing the luciferase reporter gene under the control of the cy-
clinE promoter [13] responded to E2F1 overexpression by a 6.8-
fold increase (Fig. 1F). E2F1 and p53 expression levels were moni-
tored by Western blot (Fig. 1G). These results indicate that E2F1 is
able to activate p53 transcription in HeLa cells through the distal
E2F1 BS-2 site in this context and that p53 and/or p73 do not con-
tributed to p53 promoter activation under these conditions (1.7-
fold increase).
We next investigated the effects of E2F1 over-expression on
endogenous p53 mRNA levels. Ectopic expression of E2F1 in HeLa
cells led to a signiﬁcant increase (8-fold) in endogenous p53 mRNA
level (Fig. 1H). This increase is likely due to a direct effect of E2F1
binding on the p53 promoter but could also be due, at least in part,
to p53 itself on its own promoter. However p53 protein levels are
low in HeLa cells due to the partial disruption of the p53 pathway
by the HPV18 E6 protein that targets the p53 protein to the protea-
some [14]. In addition, p73 did not signiﬁcantly increased p53
mRNA levels. Effectively, a siRNA directed against p73 failed to
modify p53 mRNA levels when E2F1 was overexpressed (Fig. 1H).
The efﬁciency of the p73 siRNA was assessed by RT-qPCR and dem-
onstrated a 83% decrease in p73 mRNA level (Fig. 1H, right) corre-
lated with a low p73 protein level (data not shown). In order to
determine the role of E2F1 under a genotoxic stress, binding of
E2F1 on the p53 promoter upon etoposide treatment was analyzed
(Fig. 2A). HeLa cells were transfected by siRNA (scrambled or direc-
ted against E2F1) and treated or not by etoposide (4 h at 50 lM). Cell
extracts were then subjected to chromatin immunoprecipitation.
Under control condition (siSCR, untreated cells) binding of E2F1
on the p53 promoter was observed only on the E2F1 BS-2 as pre-
sented in Fig. 1B. Etoposide treatment induced a strong recruitment
of E2F1 on the E2F1BS-2 binding site (230% increase). However, no
binding of E2F1 could be detected on the E2F1 BS-1 binding site
even under genotoxic stress. HeLa cells transfected by a siRNAdirec-
ted against E2F1 abolishedmost of the binding that was observed in
untreated and etoposide treated cells demonstrating the speciﬁcity
of the E2F1 immuno-precipitation. Similarly, an increase of E2F1
binding upon etoposide treatment compared to control conditions
was observed for the cyclin E and SKP2 promoters andwas impaired
when the treated and non treated cells were transfected by the E2F1
siRNA. As a negative control, no E2F1 binding could be detected in a
genomic region 1.5 kb upstream of the SKP2 transcription start site
for all studied conditions.
Interestingly, the increase of enrichment for p53, cyclin E and
SKP2 E2F1 dependent promoter regions coincides with an in-
creased enrichment with phosphorylated RNA polymerase II (P-
Pol II) immunoprecipitation (Fig. 2B). For untreated cells transfec-
ted with a scrambled siRNA, the presence of P-Pol II was detected
at the E2F1 dependent promoter region of the p53, cyclin E, SKP2
promoters and for the albumin promoter. When the cells were
transfected by the scrambled siRNA and treated by etoposide the
recruitment of P-Pol II was strongly increased for E2F1 dependent
promoters (e.g. a 300% increase for p53) whereas no signiﬁcant
change was observed for the albumin promoter. Transfection by
the siRNA directed against E2F1 reduced dramatically the presence
of the P-Pol II under both conditions (untreated and etoposide trea-
ted cells), except for the E2F1 unresponsive albumin promoter.
Thus, dynamic recruitment of activated E2F1 after a genotoxic
treatment is observed on the p53 E2F1 BS-2 distal site in HeLa cells
and is able to initiate active transcription as revealed by the con-
comitant recruitment of active phosphorylated RNA polymerase
II under these conditions.
These results were corroborated by the measurement of
endogenous p53 mRNA levels that show a 3.9-fold increase underetoposide treatment (Fig. 2C, right). However this increase in p53
mRNA level upon etoposide treatment was not observed when
the cells were depleted in E2F1 (Fig. 2C left and right) indicating
that this mechanism is E2F1 dependent. At the protein level, etopo-
side treatment showed a strong increase in p53 protein level con-
comitantly with an increase in E2F1 level (Fig. 2D) when the cells
where transfected by a scrambled siRNA (siSCR). It is well estab-
lished that the increase in E2F1 protein level after etoposide
treatment is due to protein stabilization by an ATM-induced phos-
phorylation [15,16]. However when E2F1 was knocked-down by a
siRNA treatment, p53 protein levels increased but moderately
(Fig. 2D). This remaining increase is likely due to p53 protein self
induction due to its stabilization through the DNA damage path-
way that disrupts the p53-mdm2 complex [17,18].
We ﬁnally assessed whether etoposide was functionally able to
trigger apoptosis through the E2F1 pathway. For this, we measured
caspase 3 and caspase 7 activation in HeLa cells transfected by a
scrambled siRNA or a siRNA directed against E2F1 and treated or
not by different concentrations of etoposide (Fig. 3A). In E2F1 de-
pleted HeLa cells, a 3-fold decrease for a 25 lM etoposide treat-
ment or a 4-fold decrease for a 50 lM treatment in caspase
activity was observed. Similar results were obtained when a siRNA
directed against p53 was transfected whereas a siRNA targeting
p73 moderately contibuted to reduce the sensibility to etoposide.
These results were conﬁrmed by an annexin/propidium iodide
(PI) staining experiment (Fig. 3B). Etoposide treatment induced a
5-fold increase in apoptotic cell number (PI and annexin positive
cells) under control conditions (siSCR ± etoposide) whereas cells
transfected by a siRNA against E2F1 or p53 displayed only a two
fold increase in apoptotic cell number upon etoposide treatment.
Again, depletion of p73 did not signiﬁcantly protect cells from eto-
poside (3.8-fold increase of apoptosis). These results indicate that
the E2F1/p53 pathway is still functional in HPV positive HeLa cells
as a disruption of this pathway by E2F1 or p53 siRNA protects cells
from apoptosis and that these tumor cells can be efﬁciently tar-
geted by chemotherapeutic agents like etoposide.
To conclude, we showed that the DNA damaging chemothera-
peutic agent etoposide induces p53 expression that, at least in part,
occurs at the transcriptional level as demonstrated by the lucifer-
ase reporter, RTqPCR and ChIP experiments. Moreover in HeLa
cells, this activation occurs mainly through the E2F1 pathway
while the p53/p73 positive feedback loop slightly contributes to
the regulation of the p53 gene transcription. Importantly, interfer-
ence with the E2F1-mediated apoptotic pathway strongly impairs
the p53-mediated apoptotic response to the DNA damaging agent
etoposide. This study highlights the importance of the E2F1 path-
way in mediating the apoptosis of Human papillomavirus positive
carcinoma cells under genotoxic stress. Interestingly, HeLa cells are
HPV-18 positive and thus produce E6 and E7 transforming pro-
teins. E7 protein disrupts Rb/E2F repressor complexes and acti-
vates E2F1-driven transcription whereas E6 protein accelerates
p53 ubiquitin-mediated degradation [19–23,12]. It appears that
under a genotoxic stress, E6 activity is not sufﬁcient to modulate
the E2F1/p53 pathway leading to a strong E2F1 and RNA polymer-
ase II recruitment and consequently a p53 level responsible of
caspases activation and thus apoptosis. Interestingly, in HeLa cells,
when E6 alone was repressed, apoptosis occurred [24,25]. More-
over, HPV 16 E6 and E7 proteins highly sensitize Human Keratino-
cytes to apoptosis (induction of caspase 3 activity) induced by
chemotherapeutic agents: this increase in sensitivity may relate
to both the higher level of p53 protein as well as the binding of
E7 to the active form of pRb [26]. However, under normal condi-
tions, one can imagine that the E6 protein lowers efﬁciently the
p53 protein level whereas the E7 protein induces the E2F1-driven
transcription leading for example to a cyclin E protein level able to
disturb cell cycle regulation. In addition, it is interesting to note
3194 A. Massip et al. / FEBS Letters 587 (2013) 3188–3194that the high binding afﬁnity to pRb for the E7 protein of the high
risk group HPV correlates with the transforming potential of E7
[27].
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